Form 4: C4 Therapeutics CFO Kendra Adams Reports Stock Transactions

Kendra Adams, CFO of C4 Therapeutics, reports the vesting of performance restricted stock units and shares withheld for tax obligations.

Summary

• On November 7, 2024, Kendra Adams, the Chief Financial Officer of C4 Therapeutics, Inc. (CCCC), reported transactions involving the company's common stock.
• Adams acquired 3,750 shares of common stock upon the vesting of performance restricted stock units (PRSUs).
• The company withheld 1,102 shares to satisfy tax withholding obligations related to the vesting of these PRSUs at a price of $6.04.
• Following these transactions, Adams directly owns 84,439 shares of C4 Therapeutics common stock and 10,500 performance restricted stock units.
• The PRSUs vest upon the satisfaction of share price and discovery/clinical milestones.

Sentiment

Score: 6

Explanation: The document reflects routine insider transactions related to executive compensation. The sentiment is neutral as it doesn't indicate significant positive or negative developments for the company.

Positives

• The vesting of performance restricted stock units indicates that certain performance milestones have been met.

Future Outlook

The vesting of the remaining PRSUs is contingent upon the achievement of future share price and discovery/clinical milestones.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests between management and shareholders.

Stakeholder Impact

• The vesting of PRSUs aligns management's interests with shareholders by incentivizing them to achieve share price and clinical milestones.

Key Dates